Hideko Ohama

Matsuyama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 164 publications

Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 29, 2026

Development of a Risk-Estimation Model for Identifying Patients at Risk of Early Skeletal Muscle Mass Loss in Chronic Liver Disease.

Development of a Risk-Estimation Model for Identifying Patients at Risk of Early Skeletal Muscle Mass Loss in Chronic Liver Disease.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 19, 2026

Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

Journal: Oncology

Published: April 19, 2026

Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: April 07, 2026

Identifying a biologically high-risk subgroup of anatomically resectable hepatocellular carcinoma.

Identifying a biologically high-risk subgroup of anatomically resectable hepatocellular carcinoma.

Journal: Hepatology international

Published: March 22, 2026

Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma.

Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: March 17, 2026

Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study.

Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study.

Journal: Hepatology (Baltimore, Md.)

Published: January 27, 2026

Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

Journal: Journal of gastroenterology and hepatology

Published: January 19, 2026

Changes in the Liver Fibrosis of Patients Who Develop Hepatocellular Carcinoma After a Sustained Virologic Response to Hepatitis C Virus Infection.

Changes in the Liver Fibrosis of Patients Who Develop Hepatocellular Carcinoma After a Sustained Virologic Response to Hepatitis C Virus Infection.

Journal: Journal of medical virology

Published: January 13, 2026

Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab.

Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: January 13, 2026

Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: January 12, 2026

Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study.

Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: December 09, 2025

Showing 1-12 of 164

Last Updated: 09/26/2026